Clinical practice and outcome of radiotherapy for advanced esophageal squamous cell carcinoma between 2002 and 2018 in China: the multi-center 3JECROG Survey

References

• Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941–1953.
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132.
   PubMed Web of Science ®Google Scholar
• Pennathur A, Gibson MK, Jobe BA, et al. Oesophageal carcinoma. Lancet. 2013;381(9864):400–412.
   PubMed Web of Science ®Google Scholar
• Arnold M, Soerjomataram I, Ferlay J, et al. Global incidence of oesophageal cancer by histological subtype in 2012. Gut. 2015;64(3):381–387.
   PubMed Web of Science ®Google Scholar
• Coia LR, Minsky BD, John MJ, et al. The evaluation and treatment of patients receiving radiation therapy for carcinoma of the esophagus. Cancer. 1999;85(12):2499–2505.
   PubMed Web of Science ®Google Scholar
• Tanisada K, Teshima T, Ikeda H, et al. A preliminary outcome analysis of the patterns of care study in Japan for esophageal cancer patients with special reference to age: non surgery group. Int J Radiat Oncol. 2000;46(5):1223–1233.
   PubMed Web of Science ®Google Scholar
• Coia LR, Minsky BD, Berkey BA, et al. Outcome of patients receiving radiation for cancer of the esophagus: results of the 1992-1994 patterns of care study. J Clin Oncol. 2000;18(3):455–455.
   PubMed Web of Science ®Google Scholar
• Suntharalingam M, Moughan J, Coia LR, et al. Outcome results of the 1996-1999 patterns of care survey of the national practice for patients receiving radiation therapy for carcinoma of the esophagus. J Clin Oncol. 2005;23(10):2325–2331.
   PubMed Web of Science ®Google Scholar
• Nishimura Y, Koike R, Ogawa K, et al. Clinical practice and outcome of radiotherapy for esophageal cancer between 1999 and 2003: the Japanese Radiation Oncology Study Group (JROSG) Survey. Int J Clin Oncol. 2012;17(1):48–54.
   PubMed Web of Science ®Google Scholar
• Tachimori Y, Ozawa S, Numasaki H, et al. Comprehensive registry of esophageal cancer in Japan, 2012. Esophagus. 2019;16(3):221–245.
   PubMed Web of Science ®Google Scholar
• Li C, Ni W, Wang X, et al. A phase I/II radiation dose escalation trial using simultaneous integrated boost technique with elective nodal irradiation and concurrent chemotherapy for unresectable esophageal Cancer. Radiat Oncol. 2019;14(1):48.
   PubMed Web of Science ®Google Scholar
• Greene FL, Page DL, Fleming ID, et al. AJCC cancer staging manual. 6th ed. New York: Springer; 2002.
   Google Scholar
• Naik KB, Liu Y, Goodman M, et al. Concurrent chemoradiotherapy with or without surgery for patients with resectable esophageal cancer: an analysis of the National Cancer Data Base. Cancer. 2017;123(18):3476–3485.
   PubMed Web of Science ®Google Scholar
• De-Ren S. Ten-year follow-up of esophageal cancer treated by radical radiation therapy: analysis of 869 patients. Int J Radiat Oncol. 1989;16(2):329–334.
   PubMed Web of Science ®Google Scholar
• Li C, Wang X, Wang X, et al. A multicenter phase III study comparing Simultaneous Integrated Boost (SIB) radiotherapy concurrent and consolidated with S-1 versus SIB alone in elderly patients with esophageal and esophagogastric cancer – the 3JECROG P-01 study protocol. BMC Cancer. 2019;19(1):397.
   PubMed Web of Science ®Google Scholar
• Gao L, Wang X, Han W, et al. A multicenter prospective phase III clinical randomized study of simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal cancer: 3JECROG P-02 study protocol. BMC Cancer. 2020;20(1):901.
   PubMed Web of Science ®Google Scholar
• Wang X, Ge X, Wang X, et al. S-1–based chemoradiotherapy followed by consolidation chemotherapy with S-1 in elderly patients with esophageal squamous cell carcinoma: a multicenter phase II. Trial. Front Oncol. 2020;10:1–11.
   PubMed Web of Science ®Google Scholar
• Chen M, Liu X, Han C, et al. Does chemoradiotherapy benefit elderly patients with esophageal squamous cell cancer? A propensity-score matched analysis on multicenter data (3JECROG R-03A). BMC Cancer. 2020;20(1):36.
   PubMed Web of Science ®Google Scholar
• Yamasaki M, Miyata H, Miyazaki Y, et al. Evaluation of the nodal status in the 7th edition of the UICC-TNM classification for esophageal squamous cell carcinoma: proposed modifications for improved survival stratification. Ann Surg Oncol. 2014;21(9):2850–2856.
   PubMed Web of Science ®Google Scholar
• Nomura M, Shitara K, Kodaira T, et al. Prognostic impact of the 6th and 7th American Joint Committee on Cancer TNM staging systems on esophageal cancer patients treated with chemoradiotherapy. Int J Radiat Oncol. 2012;82(2):946–952.
   PubMed Web of Science ®Google Scholar
• Jingu K, Umezawa R, Matsushita H, et al. Chemoradiotherapy for T4 and/or M1 lymph node esophageal cancer: experience since 2000 at a high-volume center in Japan. Int J Clin Oncol. 2016;21(2):276–282.
   PubMed Web of Science ®Google Scholar
• Herskovic A, Martz K, Al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326(24):1593–1598.
   PubMed Web of Science ®Google Scholar
• Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA. 1999;281(17):1623–1627.
   PubMed Web of Science ®Google Scholar
• Chen M, Shen M, Lin Y, et al. Adjuvant chemotherapy does not benefit patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy. Radiat Oncol. 2018;13(1):150.
   PubMed Web of Science ®Google Scholar
• Koh HK, Park Y, Koo T, et al. Adjuvant chemotherapy and dose escalation in definitive concurrent chemoradiotherapy for esophageal squamous cell carcinoma. Anticancer Res. 2020;40(3):1771–1778.
   PubMed Web of Science ®Google Scholar
• Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20(5):1167–1174.
   PubMed Web of Science ®Google Scholar
• Welsh J, Settle SH, Amini A, et al. Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. Cancer. 2012;118(10):2632–2640.
   PubMed Web of Science ®Google Scholar
• Chang C-L, Tsai H-C, Lin W-C, et al. Dose escalation intensity-modulated radiotherapy–based concurrent chemoradiotherapy is effective for advanced-stage thoracic esophageal squamous cell carcinoma. Radiother Oncol. 2017;125(1):73–79.
   PubMed Web of Science ®Google Scholar
• Chen C-Y, Li C-C, Chien C-R. Does higher radiation dose lead to better outcome for non-operated localized esophageal squamous cell carcinoma patients who received concurrent chemoradiotherapy? A population based propensity-score matched analysis. Radiother Oncol. 2016;120(1):136–139.
   PubMed Web of Science ®Google Scholar
• Song T, Liang X, Fang M, et al. High-dose versus conventional-dose irradiation in cisplatin-based definitive concurrent chemoradiotherapy for esophageal cancer: a systematic review and pooled analysis. Exp Rev Anticancer Ther. 2015;15(10):1157–1169.
   PubMed Web of Science ®Google Scholar
• Rice TW, Chen L-Q, Hofstetter WL, et al. Worldwide Esophageal Cancer Collaboration: pathologic staging data. Dis Esophagus. 2016;29(7):724–733.
   PubMed Web of Science ®Google Scholar